Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to Sepsis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Sharifov, Oleg F ^a   Xu, Xin ^a   Gaggar, Amit ^a,b   Grizzle, William E ^c   Mishra, Vinod K ^a   Honavar, Jaideep ^a   Litovsky, Silvio H ^c   Palgunachari, Mayakonda N ^a   White, C Roger ^a   Anantharamaiah, G M ^a   Gupta, Himanshu ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ENDOTOXIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; L 4F; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PEPTIDOMIMETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTOXEMIA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE ACTIVATION; LIVER INJURY; LUNG INJURY; MALE; MORTALITY; NONHUMAN; RAT; SEPSIS; SURVIVAL RATE;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; ENDOTOXEMIA; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; LIVER; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; PEPTIDOMIMETICS; RATS; RESPIRATORY DISTRESS SYNDROME, ADULT; SUPEROXIDES; SURVIVAL ANALYSIS;

EID: 84877771780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064486     Document Type: Article

References (61)

1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, et al. (2005) Incidence and outcomes of acute lung injury. N Engl J Med 353: 1685-1693.
2. Cohen J, (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
3. Munford RS, (2006) Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol 1: 467-496.
4. Bannerman DD, Goldblum SE, (2003) Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis. American journal of physiology Lung cellular and molecular physiology 284: L899-914.
5. Baumgarten G, Knuefermann P, Schuhmacher G, Vervèolgyi V, von Rappard J, et al. (2006) Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock (Augusta, Ga) 25: 43-49.
6. Guha M, Mackman N, (2001) LPS induction of gene expression in human monocytes. Cellular signalling 13: 85-94.
7. Calkins CM, Heimbach JK, Bensard DD, Song Y, Raeburn CD, et al. (2001) TNF receptor I mediates chemokine production and neutrophil accumulation in the lung following systemic lipopolysaccharide. J Surg Res 101: 232-237.
8. Nowak M, Gaines GC, Rosenberg J, Minter R, Bahjat FR, et al. (2000) LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 278: R1202-1209.
9. Siore AM, Parker RE, Stecenko AA, Cuppels C, McKean M, et al. (2005) Endotoxin-induced acute lung injury requires interaction with the liver. Am J Physiol Lung Cell Mol Physiol 289: L769-776.
10. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, et al. (1995) Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062-1073.
11. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, et al. (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215: 356-362.
12. Bouros D, Alexandrakis MG, Antoniou KM, Agouridakis P, Pneumatikos I, et al. (2004) The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm Med 4: 6.
13. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA, (2002) Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17: 463-467.
14. Read TE, Harris HW, Grunfeld C, Feingold KR, Calhoun MC, et al. (1993) Chylomicrons enhance endotoxin excretion in bile. Infect Immun 61: 3496-3502.
15. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE, (2003) Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 44: 2339-2348.
16. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, et al. (1995) Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 63: 2041-2046.
17. Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ, (2001) Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun 71: 3280-3284.
18. van Leeuwen HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, et al. (2003) Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 31: 1359-1366.
19. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, et al. (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96: 2758-2767.
20. Wu A, Hinds CJ, Thiemermann C, (2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21: 210-221.
21. Novak F, Vavrova L, Kodydkova J, Novak F Sr, Hynkova M, et al. (2010) Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med 10: 21-25.
22. Draganov D, Teiber J, Watson C, Bisgaier C, Nemzek J, et al. (2010) PON1 and oxidative stress in human sepsis and an animal model of sepsis. Adv Exp Med Biol 660: 89-97.
23. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, et al. (1996) Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184: 1601-1608.
24. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL, (1993) In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 90: 12040-12044.
25. McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, et al. (2003) Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20: 551-557.
26. Yan YJ, Li Y, Lou B, Wu MP, (2006) Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 79: 210-215.
27. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, et al. (2001) A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 42: 545-552.
28. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, et al. (2004) Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 15: 645-649.
29. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, et al. (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49: 2302-2311.
30. Gupta H, Dai L, Datta G, Garber DW, Grenett H, et al. (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97: 236-243.
31. Dai L, Datta G, Zhang Z, Gupta H, Patel R, et al. (2010) The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 51: 2695-2705.
32. Zhang Z, Datta G, Zhang Y, Miller AP, Mochon P, et al. (2009) Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 297: H866-873.
33. Sharifov OF, Xu X, Gaggar A, Grizzle WE, Palgunachari MN, et al. (2012) ApoA-I Mimetic Peptide, L-4F Inhibits Endotoxin-Induced Acute Lung Injury And Systemic Inflammation by Inhibiting Neutrophil Activation. Am J Respir Crit Care Med 185: A2213.
34. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, et al. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. Journal of lipid research 42: 1096-1104.
35. Fowler AA, Hamman RF, Zerbe GO, Benson KN, Hyers TM, (1985) Adult respiratory distress syndrome. Prognosis after onset. Am Rev Respir Dis 132: 472-478.
36. Xu X, Jackson PL, Tanner S, Hardison MT, Abdul Roda M, et al. (2011) A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One 6: e15781.
37. Iovine NM, Elsbach P, Weiss J, (1997) An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci U S A 94: 10973-10978.
38. Mishra VK, Palgunachari MN, Datta G, Phillips MC, Lund-Katz S, et al. (1998) Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes. Biochemistry 37: 10313-10324.
39. Garber DW, Kulkarni KR, Anantharamaiah GM, (2000) A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res 41: 1020-1026.
40. Blatter Garin MC, Moren X, James RW, (2006) Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 47: 515-520.
41. Murphy AJ, Woollard KJ, Suhartoyo A, Stirzaker RA, Shaw J, et al. (2011) Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 31: 1333-1341.
42. Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, et al. (2010) Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 298: C1538-1548.
43. White CR, Smythies LE, Crossman DK, Palgunachari MN, Anantharamaiah GM, et al. (2012) Regulation of Pattern Recognition Receptors by the Apolipoprotein A-I Mimetic Peptide 4F. Arterioscler Thromb Vasc Biol 32: 2631-2639.
44. Haddad IA, Ordovas JM, Fitzpatrick T, Karathanasis SK, (1986) Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes. J Biol Chem 261: 13268-13277.
45. Morishima A, Ohkubo N, Maeda N, Miki T, Mitsuda N, (2003) NFkappaB regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha. J Biol Chem 278: 38188-38193.
46. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, et al. (2009) Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 284: 30825-30835.
47. White CR, Datta G, Buck AK, Chaddha M, Reddy G, et al. (2012) Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F. J Lipid Res 53: 1576-1587.
48. Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP, (2011) Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res 52: 435-450.
49. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, et al. (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590.
50. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V, (2010) HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) 18: 1079-1084.
51. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, et al. (2010) L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 4: 139-148.
52. Vakili L, Hama S, Kim JB, Tien D, Safarpoor S, et al. (2010) The Effect of HDL Mimetic Peptide 4F on PON1. Adv Exp Med Biol 660: 167-172.
53. Nandedkar SD, Weihrauch D, Xu H, Shi Y, Feroah T, et al. (2011) D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res 52: 499-508.
54. Kwon WY, Suh GJ, Kim KS, Kwak YH, Kim K, (2012) 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg 72: 1576-1583.
55. Floer M, Gotte M, Wild MK, Heidemann J, Gassar ES, et al. (2010) Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol 176: 146-157.
56. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, et al. (2004) Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109: 3215-3220.
57. Ware LB, Matthay MA, (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349.
58. ARDS-Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342: 1301-1308.
59. Gaggar A, Olman MA, (2006) Biologic markers of mortality in acute lung injury. Clin Chim Acta 372: 24-32.
60. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, et al. (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49: 1344-1352.
61. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, et al. (2011) Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 52: 361-373.